Study of MT027 in Patients with Recurrent or Progressive High-grade Glioma
NCT06737146
·
clinicaltrials.gov ↗
PHASE1
Phase
NOT_YET_RECRUITING
Status
12
Enrollment
INDUSTRY
Sponsor class
Conditions
High-grade Glioma
Interventions
DRUG:
MT027 cells suspension
Sponsor
Suzhou Maximum Bio-tech Co., Ltd.